137 related articles for article (PubMed ID: 25633738)
1. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III.
Iskandar ME; Bonomo G; Avadhani V; Persky M; Lucido D; Wang B; Marti JL
Surgery; 2015 Mar; 157(3):510-7. PubMed ID: 25633738
[TBL] [Abstract][Full Text] [Related]
2. Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Kuru B; Atmaca A; Tarim IA; Kefeli M; Topgul K; Yoruker S; Elmali M; Danaci M
Eur J Surg Oncol; 2016 Jan; 42(1):87-93. PubMed ID: 26527545
[TBL] [Abstract][Full Text] [Related]
3. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
Wong LQ; Baloch ZW
Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
[TBL] [Abstract][Full Text] [Related]
5. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology.
Maia FF; Matos PS; Pavin EJ; Zantut-Wittmann DE
Clin Endocrinol (Oxf); 2015 Mar; 82(3):439-44. PubMed ID: 24930423
[TBL] [Abstract][Full Text] [Related]
6. Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
Yoo MR; Gweon HM; Park AY; Cho KE; Kim JA; Youk JH; Son EJ
PLoS One; 2015; 10(6):e0130138. PubMed ID: 26115096
[TBL] [Abstract][Full Text] [Related]
7. Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology.
Chen JC; Pace SC; Chen BA; Khiyami A; McHenry CR
Surgery; 2012 Dec; 152(6):1037-44. PubMed ID: 23040711
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Nodules: Nondiagnostic Cytologic Results according to Thyroid Imaging Reporting and Data System before and after Application of the Bethesda System.
Yoon JH; Lee HS; Kim EK; Moon HJ; Kwak JY
Radiology; 2015 Aug; 276(2):579-87. PubMed ID: 25848904
[TBL] [Abstract][Full Text] [Related]
9. Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.
Rossi M; Lupo S; Rossi R; Franceschetti P; Trasforini G; Bruni S; Tagliati F; Buratto M; Lanza G; Damiani L; Degli Uberti E; Zatelli MC
Endocrine; 2017 Jul; 57(1):98-107. PubMed ID: 27623969
[TBL] [Abstract][Full Text] [Related]
10. The national rate of malignancy among Bethesda III, IV, and V thyroid nodules is higher than expected: A NSQIP analysis.
Delman AM; Turner KM; Ammann AM; Sisak S; Farooqui Z; Holm TM
Surgery; 2023 Mar; 173(3):645-652. PubMed ID: 36229250
[TBL] [Abstract][Full Text] [Related]
11. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
[TBL] [Abstract][Full Text] [Related]
12. Rates of Malignancy in Cytology Indeterminate Thyroid Nodules: A Single Center Surgical Series.
Baraf L; Avidor Y; Bahat Dinur A; Yoel U; Samueli B; Joshua BZ; Fraenkel M
Isr Med Assoc J; 2023 Feb; 25(2):147-151. PubMed ID: 36841986
[TBL] [Abstract][Full Text] [Related]
13. Follicular lesion of undetermined significance in thyroid FNA revisited.
Walts AE; Mirocha J; Bose S
Diagn Cytopathol; 2014 Jan; 42(1):18-22. PubMed ID: 23894017
[TBL] [Abstract][Full Text] [Related]
14. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens.
Olson MT; Boonyaarunnate T; Aragon Han P; Umbricht CB; Ali SZ; Zeiger MA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1450-7. PubMed ID: 23436916
[TBL] [Abstract][Full Text] [Related]
15. Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center.
Godoi Cavalheiro B; Kober Nogueira Leite A; Luongo de Matos L; Palermo Miazaki A; Marcel Ientile J; Aurelio V Kulcsar M; Roberto Cernea C
Int J Endocrinol Metab; 2018 Jan; 16(1):e12871. PubMed ID: 29696036
[TBL] [Abstract][Full Text] [Related]
16. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules.
Richmond BK; O'Brien BA; Mangano W; Thompson S; Kemper S
Am Surg; 2012 Jun; 78(6):706-10. PubMed ID: 22643269
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category IV (FN/SFN).
Kuru B; Kefeli M
Diagn Cytopathol; 2018 Jun; 46(6):489-494. PubMed ID: 29524316
[TBL] [Abstract][Full Text] [Related]
18. A histological assessment of the Bethesda system for reporting thyroid cytopathology (2010) abnormal categories: a series of 219 consecutive cases.
Tepeoğlu M; Bilezikçi B; Bayraktar SG
Cytopathology; 2014 Feb; 25(1):39-44. PubMed ID: 23438201
[TBL] [Abstract][Full Text] [Related]
19. What is the malignancy risk for atypia of undetermined significance? Three years' experience at a university hospital in Turkey.
Gocun PU; Karakus E; Bulutay P; Akturk M; Akin M; Poyraz A
Cancer Cytopathol; 2014 Aug; 122(8):604-10. PubMed ID: 24890894
[TBL] [Abstract][Full Text] [Related]
20. Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective.
Zahid A; Shafiq W; Nasir KS; Loya A; Abbas Raza S; Sohail S; Azmat U
J Clin Transl Endocrinol; 2021 Mar; 23():100250. PubMed ID: 33643850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
